Systemic administration of mexiletine for attenuation of cerebral vasospasm following experimental subarachnoid haemorrhage

Acta Neurochirurgica

Volumn 142, Issue 4, 2000, Pages 455-461

  Caner, Hakan ^a   Kwan, A L ^b   Bavbek, M ^a   Kilinc, K ^c   Durieux, M ^b   Lee, K ^b   Kassell, N F ^b  

^a BASKENT UNIVERSITY   (Turkey)

^b UNIVERSITY OF VIRGINIA   (United States)

^c HACETTEPE UNIVERSITY   (Turkey)

Author keywords

Cerebral vasospasm; Lipid peroxidation; Mexiletine; Subarachnoid haemorrhage

Indexed keywords

ENDOTHELIN 1; LYSOPHOSPHATIDIC ACID; MEXILETINE; POTASSIUM CHLORIDE;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTERIAL BLOOD; ARTERY CONSTRICTION; ARTERY DILATATION; ARTICLE; BASILAR ARTERY; BRAIN VASOSPASM; CISTERNA MAGNA; CONTROLLED STUDY; MICROSCOPY; NONHUMAN; PRIORITY JOURNAL; RABBIT; SUBARACHNOID HEMORRHAGE;

EID: 0034033681     PISSN: 00016268     EISSN: None     Source Type: Journal    
DOI: 10.1007/s007010050457     Document Type: Article

References (25)

1. 1. Alborch E, Salom JB, Torregrosa G (1995) Calcium channels in cerebral arteries. Pharm Ther 68: 1-34
2. 2. Asano T, Matsui T, Takuwa Y (1990) Reappraisal of the role of lipid peroxidation in the pathogenesis of vasospasm. Relevance to protein kinase C. In: Sana K, Takakura A, Kassell NF, Sasaki T (eds) Cerebral Vasospasm Proceedings of the IVth International Conference on Cerebral Vasospasm Tokyo, 15-18 May, Tokyo. University of Tokyo Press, pp 65-70
3. 3. Bavbek M, Nietgen GW, Bogaev C, Fineman MB, Polin R, Chen ZF, Lee KS, Kassell NF, Durieux ME (1997) Increased lysophosphatidate levels in CSF after subarachnoid hemorrhage. AANS poster book, p 30, (abstract)
4. 4. Caner H, Oruckaptan H, Bolay H, Kamer Kilinç, Sassan Senaati, Kemal Benli, Ayşe Ayhan (1991) The role of lipid peroxidation in the genesis of vasospasm secondary to subarachnoid haemorrhage. Kobe J Med Sci 37: 13-19
5. 5. Caner H, Sannati S, Bolay H, Kamer Kilinç, Kemal Benli (1992) Protective effect of the iron chelator deferoxamine on cerebral vasospasm. Vascular Surgery 26: 665-672
6. 6. Cook DA (1995) Mechanisms of cerebral vasospasm in subarachnoid haemorrhage. Pharmac Ther 66: 259-284
7. 7. Demirpençe D, Caner H, Bavbek M, Kilinç K (1999) Antioxidant action of antiaritmic drug mexiletine in brain membrane. Jpn J Pharmacol 81: 7-11
8. 8. Dohi Y, Kojima M, Sato K (1994) Vasorelaxant effect of mexiletine in mesenteric resistance arteries of rats. Br J Pharmacol 111:673-680
9. 9. Foley PL, Caner HH, Kassell NF et al (1994) Reversal of subarachnoid haemorrhage-induced vasoconstriction with an endothelin receptor antagonist. Neurosurgery 34: 108-113
10. 10. Kanamaru K, Weir BKA, Simpson L, Witbeck T, Grace M (1991) Effect of 21-aminosteroid u-74006F on lipid peroxidation in subarachnoid clot. J Neurosurg 74: 454-459
11. 11. Kim P, Yoshimoto Y, Lino M, Tomio S, Kirino T, Nonomura Y (1996) Impaired calcium regulation of smooth muscle during chronic vasospasm following subarachnoid haemorrhage. J Cereb Blood Flow Metab 16: 334-341
12. 2+ channel antagonist, AJ-3941, of loss of endothelium-dependent relaxation after subarachnoid haemorrhage in rats. Eur J Pharmacol 315: 297-303
13. 13. Monk JP, Brogden RN (1990) Mexiletine: a review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in the treatment of arrhythmias. Drugs 40: 374-411
14. 14. Moolenaar WH (1994) LPA: a novel lipid mediator with diverse biological actions. Trend Cell Biol 4: 213-219
15. 15. Nagasako S, Hayashibara M, Katagiri Y, Iwamoto K (1992) Salivary excretion of mexiletine after bolus intravenous administration in rats. J Pharm Pharmacol 44: 55-57
16. 16. Ono K, Kiyosue T, Arita M (1986) Comparison of the inhibitory effects of mexiletine on the calcium currents of single ventricular cells. Life Sci 39: 1465-1470
17. 17. Salom JB, Torregrosa G, Miranda FJ, Alabadi JA, Alvarez C, Alborch E (1991) Effects of endothelin-I on the cerebrovascular bed of the goat. Eur J Pharmacol 192: 39-45
18. 18. Sasaki S, Ohta S, Nakamura H (1988) Free radical reaction and biological defence mechanism in the pathogenesis of prolonged vasospasm in experimental subarachnoid haemorrhage. J Cereb Blood Flow Metab 8: 1-8
19. 19. Sasaki T, Kuwabara H, Ohta S (1986) Biological defence mechanisms in the pathogenesis of prolonged vasospasm in patients with ruptured intracranial aneurysms. Stroke 17: 198-202
20. + channels. Br J Pharmacol 115: 381-382
21. 21. Shirayama T, Inoue D, Inoue M, Tatsumi T, Yamahara Y, Asayama J, Katsume H, Nakagawa M (1991) Electrophysiological effects of sodium channel blockers in the guinea pig left atrium. J Pharmacol Exp Ther 259: 884-893
22. 22. Vaughan WEM (1984) A classification of antiarrhythmic actions reassessed after a decade of new drugs J Clin Pharmacol 24: 129-147
23. 23. Vollmer DG, Hongo K, Ogawa H, Tsukahara T, Kassell NF (1991) A study of the effectiveness of the iron-chelating agent deferoxamine as vasospasm prophylaxis in a rabbit model of subarachnoid haemorrhage. Neurosurgery 28: 27-32
24. 24. Wedmore CV, Williams TJ (1981) Control of vascular permeability by polymorphonuclear leukocytes in inflammation. Nature 289: 646
25. + channel activator cromakalim. Stroke 27: 311-316